Skip to content

DMT: all studies

Page 126 of 160: studies 1,251 to 1,260 of 1,594, newest first. Back to the DMT overview

Research

It’s Tea Time: Interference of Ayahuasca Brew on Discriminative Learning in Zebrafish

Frontiers in Behavioral Neuroscience August 27, 2018 Bruno Lobão‐soares, Paulianny Eduardo-Da-Silva, Hugo Amarilha et al. 15 citations

Ayahuasca is a psychoactive brew traditionally used in shamanistic and vegetalistic rituals and has recently received lot of attention due to potential cognitive benefits. Ayahuasca effects are caused by the synergistic interaction of β-carbolines (harmine, harmaline and tetrahydroarmine) contained in Banisteriopsis caapi stalks combined with the N,N-dimethyltryptamine (DMT) from Psychotria...

Analogues de l’ayahuasca : le chamanisme de synthèse

Annales de Toxicologie Analytique August 21, 2018 Jérôme Langrand, Laurène Dufayet, A. Villa et al.

Objectif L’ayahuasca est un breuvage psychedelique originaire du bassin amazonien et utilise dans des rites chamaniques. Il consiste en l’ingestion successive de 2 decoctions vegetales, l’une ayant un effet inhibiteur de la monoamine oxydase (IMAO), l’autre contenant de la dimethyltryptamine (DMT) responsable des effets hallucinogenes. Son utilisation en Europe est limitee par la reglementation...

“Ayahuasca turned on my mind’s eye”: Enhanced visual imagery after ayahuasca intake in a man with “blind imagination” (aphantasia)

Journal of Psychedelic Studies July 25, 2018 Rafael G. Dos Santos, Scotty Enyart, José Carlos Bouso et al. 18 citations

Aphantasia ("blind imagination") is a poorly described condition with an uncertain etiology, characterized by reduced or lack of voluntary visual imagery. Preliminary evidence in humans suggests that hallucinogenic or psychedelic drugs that act as agonists of cortical 5-HT2A receptors [lysergic acid diethylamide, psilocybin, and dimethyltryptamine (DMT)] enhance visual imagery. Interview and...

Production Options for Psilocybin: Making of the Magic

Chemistry - A European Journal July 16, 2018 Janis Fricke, Claudius Lenz, Jonas Wick et al. 52 citations

Abstract The fungal genus Psilocybe and other genera comprise numerous mushroom species that biosynthesize psilocybin (4‐phosphoryloxy‐ N , N ‐dimethyltryptamine). It represents the prodrug to its dephosphorylated psychotropic analogue, psilocin. The colloquial term “magic mushrooms” for these fungi alludes to their hallucinogenic effects and to their use as recreational drugs. However,...

Pre-clinical interaction of ayahuasca, a brew used in spiritual movements, with morphine and propofol

Brazilian Journal of Pharmaceutical Sciences June 7, 2018 Júlia Movilla Pires, Fúlvio Rieli Mendes, Ana Paula Salum Pires et al. 10 citations

ABSTRACT Ayahuasca is a beverage with psychoactive properties used in religious and ceremonial rituals by some religious groups. The main active components of ayahuasca are dimethyltryptamine and the harmala alkaloids with β-carboline structure acting as monoamine oxidase A inhibitors. This combination produces a pronounced activation of serotonergic pathways and presents potential interaction...

Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase‐Enhanced Reactions

Chemistry - A European Journal May 11, 2018 Felix Blei, Florian Baldeweg, Janis Fricke et al. 51 citations

Abstract Psilocybin (4‐phosphoryloxy‐ N , N ‐dimethyltryptamine) is the main alkaloid of the fungal genus Psilocybe , the so‐called “magic mushrooms.” The pharmaceutical interest in this psychotropic natural product as a future medication to treat depression and anxiety is strongly re‐emerging. Here, we present an enhanced enzymatic route of psilocybin production by adding TrpB, the tryptophan...

DOI: 10.1002/chem.201801047 (opens in new tab) Psilocybin Biochemistry Stereochemistry Pharmacology +2

The psychedelic religion of mystical consciousnessReviews

Journal of Psychedelic Studies May 10, 2018 Rick J. Strassman 9 citations

With an extreme range of terms for psychedelic drugsfrom "schizotoxic" to "entheogenic" -"psychedelic," nonetheless remains the most salient one.These substances manifest or disclose aspects of the mind of those who take them as well as the mind of those who study them.Proponents for the innumerable terms for these drugs are all able to adduce supportive evidence.Necessarily, this evidence is a...

Candyflipping and Other Combinations: Identifying Drug–Drug Combinations from an Online Forum

Frontiers in Psychiatry April 30, 2018 Michael Chary, David Yi, Alex F. Manini 32 citations

Novel psychoactive substances (NPS) refer to synthetic compounds or derivatives of more widely known substances of abuse that have emerged over the last two decades. Case reports suggest that users combine substances to achieve desired psychotropic experiences while reducing dysphoria and unpleasant somatic effects. However, the pattern of combining NPS has not been studied on a large scale....

DOI: 10.3389/fpsyt.2018.00135 (opens in new tab) MDMA Hallucinogen Synthetic cannabinoids Designer drug +1

Assessment of Alcohol and Tobacco Use Disorders Among Religious Users of Ayahuasca

Frontiers in Psychiatry April 24, 2018 Paulo César Ribeiro Barbosa, Luís Fernando Tófoli, Michael P. Bogenschutz et al. 95 citations

The aims of this study were to assess the impact of ceremonial use of ayahuasca-a psychedelic brew containing N,N-dimethyltryptamine (DMT) and β-carboline -and attendance at União do Vegetal (UDV) meetings on substance abuse; here we report the findings related to alcohol and tobacco use disorder. A total of 1,947 members of UDV 18+ years old were evaluated in terms of years of membership and...

DOI: 10.3389/fpsyt.2018.00136 (opens in new tab) Ayahuasca Attendance Environmental health Demography +1

Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process

Frontiers in Pharmacology April 5, 2018 Antonio Inserra 91 citations

Ayahuasca ingestion modulates brain activity, neurotransmission, gene expression and epigenetic regulation. N,N-Dimethyltryptamine (DMT, one of the alkaloids in Ayahuasca) activates sigma 1 receptor (SIGMAR1) and others. SIGMAR1 is a multi-faceted stress-responsive receptor which promotes cell survival, neuroprotection, neuroplasticity, and neuroimmunomodulation. Simultaneously, monoamine...

DOI: 10.3389/fphar.2018.00330 (opens in new tab) Ayahuasca Memory consolidation Traumatic memories